8-K: ThermoGenesis and CBR Systems Enter Into New Manufacturing and Supply Agreement

ThermoGenesis Corp. and CBR Systems, Inc. have entered into a new three-year manufacturing and supply agreement for ThermoGenesis' AutoXpress System, replacing their prior agreement.

Summary

• ThermoGenesis Corp. and CBR Systems, Inc. have established a new Manufacture and Supply Agreement effective May 29, 2024.
• Under the agreement, ThermoGenesis will supply CBR with its AutoXpress System (AXP) for cord blood processing, including the device and disposables.
• The agreement has a three-year term with automatic one-year renewals unless either party provides a six-month notice of non-renewal.
• An Amended and Restated Technology License and Escrow Agreement was also established, modifying default conditions and removing a financial covenant related to cash balance.
• The agreement also changes the delivery timeframe for AXP products from 120 days to 90 days from the requested delivery date.
• The agreement supersedes the prior agreement between the two companies.

Sentiment

Score: 7

Explanation: The document outlines a positive business development with a new supply agreement, but there are some risks and complexities involved. The removal of the cash balance covenant is a positive sign.

Positives

• The new agreement secures a three-year supply contract for ThermoGenesis' AXP system.
• The removal of the financial covenant provides ThermoGenesis with more flexibility.
• The reduced delivery timeframe may improve CBR's operational efficiency.
• The automatic renewal clause provides long-term stability for the partnership.
• The technology license and escrow agreement provides a safety net for CBR in case of supply issues.

Negatives

• The agreement requires a six-month notice for non-renewal, which could limit flexibility for both parties.
• ThermoGenesis is required to use commercially reasonable efforts to meet CBR's orders, which may not guarantee supply in all circumstances.
• CBR may not order more than a certain amount without advance discussion and written consent from ThermoGenesis.
• The agreement includes a complex set of terms and conditions that may require careful monitoring and management.

Risks

• There is a risk of supply shortages, although ThermoGenesis is required to use commercially reasonable efforts to minimize delays.
• The agreement includes a force majeure clause that could impact supply if unforeseen events occur.
• There is a risk of disputes over product quality, pricing, or delivery, which could lead to arbitration.
• The agreement includes a complex set of terms and conditions that may require careful monitoring and management.
• The agreement is subject to regulatory compliance, which could lead to delays or changes in the future.

Future Outlook

The agreement provides a framework for a three-year supply relationship with automatic one-year renewals, indicating a long-term commitment between ThermoGenesis and CBR Systems.

Management Comments

• There are no direct quotes from management in the document, but the agreement signifies a continued partnership between the two companies.

Industry Context

This agreement is relevant to the cord blood banking industry, where reliable supply of processing systems is critical. It indicates a continued demand for ThermoGenesis' AXP system in the market.

Comparison to Industry Standards

• The agreement is a standard supply agreement in the medical device industry, with terms for pricing, delivery, and quality.
• The inclusion of a technology license and escrow agreement is a common practice to ensure business continuity in case of supply disruptions.
• The three-year term with automatic renewals is typical for long-term supply contracts in this sector.
• The agreement does not provide specific details on pricing compared to industry benchmarks, but it does include a clause for price adjustments based on manufacturing costs or the Consumer Price Index.
• The agreement does not provide specific details on delivery times compared to industry benchmarks, but it does include a clause for a 90 day delivery time.

Stakeholder Impact

• Shareholders of ThermoGenesis may view this agreement positively as it secures a long-term revenue stream.
• CBR Systems benefits from a reliable supply of the AXP system.
• Customers of CBR Systems may benefit from the continued use of the AXP system for cord blood processing.
• Employees of both companies will be involved in the implementation and management of the agreement.

Next Steps

• ThermoGenesis will begin supplying CBR with the AXP system under the new agreement.
• Both companies will establish a Joint Operating Committee (JOC) to manage the agreement.
• ThermoGenesis will continue to maintain the escrow account with the required technical information.
• The parties will review and update pricing every [**].

Key Dates

Keywords

Manufacturing Agreement, Supply Agreement, AutoXpress System, Cord Blood Processing, Technology License, Escrow Agreement, ThermoGenesis, CBR Systems, Medical Device, Healthcare